Skip to main content
. 2011 Feb 26;2(1):37–40. doi: 10.4021/wjon276e

Figure 4.

Figure 4

(a) Borderline area between both tumors showing immunoreactivity for Hep Par1 in the hepatocellular carcinoma, whereas it is negative in the neuroendocrine tumor (immunoperoxidase, × 100). (b) Neuroendocrine carcinoma showing immunoreactivity for chromogranin (immunoperoxidase, × 100).